(NASDAQ: BIAF) Bioaffinity Technologies's forecast annual revenue growth rate of -8.38% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 3.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,453.97%.
Bioaffinity Technologies's revenue in 2025 is $6,776,739.On average, 3 Wall Street analysts forecast BIAF's revenue for 2025 to be $27,932,484, with the lowest BIAF revenue forecast at $26,834,799, and the highest BIAF revenue forecast at $28,751,249.
In 2026, BIAF is forecast to generate $33,528,878 in revenue, with the lowest revenue forecast at $32,215,255 and the highest revenue forecast at $34,514,095.